Published in TB and Outbreaks Week, July 4th, 2000
"Virus variation is one of the greatest challenges in HIV-1 vaccine development," observed P. Berman and colleagues from VaxGen, Inc., California, Denver Public Health, Colorado, and Thailand. "We have employed this approach to develop two vaccines designed to be effective against the majority of viruses circulating in North America, Western Europe, and Thailand."
Berman et al. presented data from their study at the Keystone Symposium, "Novel Biological Approaches to HIV-1 Infection Based on New Insights into HIV Biology," held in Keystone, Colorado. The title of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week